Oncolytic herpes simplex virus armed with xenogeneic homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate cancer.
about
Genetic, immunological, and pharmacological strategies to generate improved oncolytic virusesOncolytic virotherapy using herpes simplex virus: how far have we come?Anti-tumor effect of oncolytic herpes simplex virus G47delta on human nasopharyngeal carcinoma.Androgen-regulated transcriptional control of sialyltransferases in prostate cancer cellsThe profile of tumor antigens which can be targeted by immunotherapy depends upon the tumor's anatomical site.Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus.Curative one-shot systemic virotherapy in murine myeloma.Designing Herpes Viruses as Oncolytics.Polysaccharide-K augments docetaxel-induced tumor suppression and antitumor immune response in an immunocompetent murine model of human prostate cancer.Recent advances in oncolytic virus design.A molecular description of acid phosphatase.Oncolytic viruses and their application to cancer immunotherapyDNA vaccination for prostate cancer: key concepts and considerations.Messenger RNA vaccine based on recombinant MS2 virus-like particles against prostate cancer.Expression of gangliosides, GD1a, and sialyl paragloboside is regulated by NF-κB-dependent transcriptional control of α2,3-sialyltransferase I, II, and VI in human castration-resistant prostate cancer cells.Sharpening the Edge for Precision Cancer Immunotherapy: Targeting Tumor Antigens through Oncolytic Vaccines.Stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy.Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies.
P2860
Q26859879-14CE1490-40FB-4F00-BFC0-E2821FD8D7B8Q26862461-71DAC2AB-1CEA-4F11-B14B-15FF5BC8D2FBQ33579396-7D399CFA-B90F-4A7C-A11B-52605559922CQ34162748-2A55604A-92BD-4B5C-BCA4-C0998B676888Q35212733-0871E6AE-C7DB-49DE-B032-4CECC925167FQ35575688-71CF8E33-FCED-4A4D-B139-C8E7E03AF327Q36139716-E6BA601F-1176-4253-B6C0-C0E6495D53C4Q36142487-54F89AAF-0EC8-46D8-ACB2-1C68CE0F5332Q36645451-49A2817E-460E-4B8F-956F-51D5DE6C7A29Q37865172-16EC2492-7949-4D12-BE03-714264CB68B5Q38017593-9A54EC9D-E1FE-4306-AE60-68DFFE230387Q38207011-B30401B3-3490-4A09-BE51-FB5CC926074AQ38544772-057746A2-82E0-495A-ACF7-6582B841A272Q39084400-B0D086EA-1616-4352-BC1F-41CB14F0D067Q39619019-1E910F0D-5EAB-46CE-8083-FA1A257F85AFQ40104793-121CA3C7-C082-4740-AA0C-429BDFDBF0C2Q42218017-97971640-FCDD-4B3C-8CCD-D2B64E3F94B7Q55085319-9AF3B16E-7FBC-4D96-AA1D-D16DCA1A7670
P2860
Oncolytic herpes simplex virus armed with xenogeneic homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate cancer.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Oncolytic herpes simplex virus ...... r efficacy in prostate cancer.
@ast
Oncolytic herpes simplex virus ...... r efficacy in prostate cancer.
@en
type
label
Oncolytic herpes simplex virus ...... r efficacy in prostate cancer.
@ast
Oncolytic herpes simplex virus ...... r efficacy in prostate cancer.
@en
prefLabel
Oncolytic herpes simplex virus ...... r efficacy in prostate cancer.
@ast
Oncolytic herpes simplex virus ...... r efficacy in prostate cancer.
@en
P2093
P2860
P356
P1433
P1476
Oncolytic herpes simplex virus ...... or efficacy in prostate cancer
@en
P2093
B J Passer
J S Buhrman
M Marinelli
R L Martuza
S Antoszczyk
P2860
P2888
P304
P356
10.1038/GT.2010.20
P577
2010-03-11T00:00:00Z